Novasep unveiled plans for a €10 million investment in a commercial fill and finish facility for viral vectors, mAbs and other low-volume biologics. The facility will be located in Seneffe, Belgium and will be operational during the second half of 2019. Fill and finish operations are critical to ensure the safety and efficacy of a drug. This step involves filling biologics into containers under aseptic conditions and is the final part of the biopharmaceutical manufacturing process, after upst...